BOSTON, April 22 /PRNewswire-FirstCall/ -- Experts from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will present key industry topics during the 18th Annual Partnerships with CROs and Other Outsourcing Providers Conference, to be held April 28 - 30, 2009 at the Rosen Shingle Creek Hotel in Orlando, Florida. Thought leaders from PAREXEL, a sponsor of the conference, will discuss best practices in partnering for collaborative solutions and achieving innovation in study design and management through adaptive trials.
A complimentary Advisory from PAREXEL Consulting, entitled Innovating Strategic Partnerships in Regulatory Affairs, will be provided at PAREXEL's Booth #240 in the exhibit hall. Attendees can visit experts from Perceptive Informatics, a subsidiary of PAREXEL and the industry's leading eClinical solutions provider, at Booth #241 to discuss Perceptive's Randomization and Trial Supply Management (RTSM) solutions. A demonstration of Perceptive's DataLabs(R) Electronic Data Capture (EDC) system will be given at the booth. The system, focused on improving the efficiency and data quality of clinical studies, incorporates the advantages and flexibility of hybrid technology, unifying paper data entry and EDC into a single clinical data management platform.
The conference program features the following sessions, which will be presented by PAREXEL experts on Thursday, April 30 from 1:15 p.m. - 2:00 p.m.:
(Track A: Partnering for Collaborative Solutions)
(Track C: Raising the Bar on Quality and Patient Safety)
For more information about PAREXEL visit www.PAREXEL.com or Booths #240 and #241 at the Partnerships with CROs Conference. More information about the conference can be found at
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2008 as filed with the SEC on February 9, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.
Contacts: Jennifer Baird, Senior Director of Public Relations PAREXEL International Tel: +781-434-4409 Email: Jennifer.Baird@PAREXEL.com Rebecca Passo SHIFT Communications Tel: +617-779-1817 Email: email@example.com
|SOURCE PAREXEL International Corporation|
Copyright©2009 PR Newswire.
All rights reserved